Research Topics Enhancing Innate and Adaptive Immunity to Combat Multiple Myeloma: Combined Use of Trispecific NK Cell Engagers (TriKEs) and Bispecific T-Cell Engagers (BiTEs) in Immunotherapy Researchers Aussara PanyaNueng-hathai...
Event Details I August 16th, 2025 Recorded VDO I August 16th, 2025 (Conference) Recorded VDO I August 16th, 2025 (Conference) Photo I August 16th, 2025 Event Details I August...
Research Topics Clinical resolution of autoimmune choroiditis and multiorgan involvement of refractory systemic lupus erythematosus patient treated with CD19CAR-T incorporated CD28/CD40 signaling molecules Researchers Jakrawadee Julamanee,Panarat Noiperm,Watsamon Uraiwan,Porntip Intapiboon,Parichat...
Research Topics Prolonged CAR-T cell expansion and stemness in heavily pretreated relapsed/refractory B-ALL and B-NHL patients treated with CD19CAR incorporated CD28/CD40 co-stimulatory molecule: A preliminary outcome of academic PSU...
Research Topics Feasibility of generation and expansion of hematopoietic stem cell-derived natural killer cells for a potential alternative cell source of cancer immunotherapy Researchers Suppanut Komjakraphan,Poonnattha Anantasaeree,Kajornkiat Maneechai,Panarat Noiperm,Watsamon...
Image by www.bangkokpost.com Chula Licenses Thai PD-1 Antibody to US Biopharma August 6, 2025 Chula Licenses Thai PD-1 Antibody to US Biopharma In a historic first, Chulalongkorn University has...
We’re excited to announce that we’ll be participating in the Vaccine and Therapeutic RNA Research Forum 2025 on 4 Aug 2025. This is a fantastic opportunity to engage with...
TTCI Researchers Present and Collaborate at the 29th Annual Meeting of the Japanese Association of Cancer Immunology July 26, 2025 TTCI Researchers Present and Collaborate at the 29th Annual...
Researchers from Chulalongkorn University have successfully established a novel human antibody heavy chain variable (VH)-only domain with potent activity against folate receptor alpha-positive solid tumor in CAR-T cell format....
Researchers from Chulalongkorn University have successfully developed MUC1-targeting CAR T cells engineered to secrete an anti-PD-1 antibody, derived from nivolumab, to enhance their effectiveness against solid tumors. These modified...